May 22, 2017 / 5:20 AM / 6 months ago

BRIEF-Innate Pharma completed the dose escalation part of its ongoing phase I trial

May 22 (Reuters) - INNATE PHARMA SA:

* COMPLETED THE DOSE ESCALATION PART OF ITS ONGOING PHASE I TRIAL EVALUATING IPH4102 IN PATIENTS WITH RELAPSED/REFRACTORY CUTANEOUS T CELL LYMPHOMAS

* NO DOSE-LIMITING TOXICITY WAS REPORTED AND THE MAXIMUM TOLERATED DOSE (MTD) WAS NOT REACHED

* THE COHORT EXPANSION PART OF THE TRIAL IN PATIENTS WITH TRANSFORMED MYCOSIS FUNGOIDES AND SÉZARY SYNDROME WILL START IN THE UPCOMING WEEKS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below